Article
TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer.
Proceedings of the National Academy of Sciences of the United States of America - 31 Aug 2010
Yao Zhan, Fenoglio Silvia, Gao Ding Cheng, Camiolo Matthew, Stiles Brendon, Lindsted Trine, Schlederer Michaela, Johns Chris, Altorki Nasser, Mittal Vivek, Kenner Lukas, Sordella Raffaella
Abstract excerpt
The epidermal growth-factor receptor (EGFR) tyrosine kinase inhibitor erlotinib has been proven to be highly effective in the treatment of nonsmall cell lung cancer (NSCLC) harboring oncogenic EGFR mutations. The majority of patients, however, will eventually develop resistance and succumb to the disease. Recent studies have identified secondary mutations in the EGFR (EGFR T790M) and amplification of the...
Topics
- Animals
- Base Sequence
- Carcinoma, Non-Small-Cell Lung
- Cell Line
- Cell Line, Tumor
- Cell Movement
- Cell Survival
- Drug Resistance, Neoplasm
- Epithelial Cells